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Abstract
Coffee consumption is associated with a lower risk of type 2 diabetes. We tested the hypothesis that this is
mediated by incretin hormones by measuring the acute effects of decaffeinated coffee and coffee components on
GLP-1 and GIP concentrations. A randomized cross-over trial of the effects of 12 g decaffeinated coffee, 1 g
chlorogenic acid, 500 mg trigonelline, and placebo on total and intact GLP-1 and GIP concentrations during an
oral glucose tolerance test took place in fifteen overweight men. No treatment significantly affected the overall
GLP-1 or GIP secretion pattern following an OGTT relative to placebo. Decaffeinated coffee slightly increased total
GLP-1 concentration 30 minutes after ingestion (before the OGTT) relative to placebo (2.7 pmol/L, p = 0.03), but
this change did not correspond with changes in glucose or insulin secretion. These findings do not support the
hypothesis that coffee acutely improves glucose tolerance through effects on the secretion of incretin hormones.
Chronic effects of coffee and its major components still need to be investigated.
Findings
In prospective cohort studies, higher coffee consumption
has been associated with a lower risk of type 2 diabetes
[1,2]. Results were similar for caffeinated and decaffei-
nated coffee, suggesting that components other than caf-
feine are responsible for this association. Coffee is a
major source of the phenolic compound chlorogenic acid
[3] and the vitamin B3 precursor trigonelline [4] which
have been shown to reduce blood glucose concentrations
in animal studies [5-7]. One of the putative mechanisms
underlying the beneficial effects of coffee on glucose
homeostasis could include a stimulatory effect on the
incretin hormones glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic peptide (GIP).
Coffee components may affect GLP-1 secretion by
delaying glucose absorption, resulting in a higher expo-
sure of the distal ileum to glucose, and therefore sti-
mulation of the intestinal K cells [8]. One study found
that decaffeinated coffee increased GLP-1 concentra-
tions [9] and two studies found that both decaffeinated
coffee and caffeinated coffee intake decreased GIP
concentrations [9,10]. These results suggest that coffee
may exert a glucose-lowering response mediated by sti-
mulating incretin hormones. Data on the effects of
chlorogenic acid and trigonelline on incretin concen-
trations are lacking. We therefore investigated the
acute effects of decaffeinated coffee and the coffee
components chlorogenic acid and trigonelline on total
and intact GLP-1 and GIP concentrations in humans.
Fifteen male, healthy, non-smoking, overweight (body
mass index 25.0-35.0 kg/m2) coffee consumers were
enrolled. All subjects provided written informed con-
sent. The study design has been described previously
[11]. Briefly, four supplements were tested in this cross-
over trial: 12 grams of decaffeinated instant coffee gran-
ules (Nescafé Gold, Nestlé, The Netherlands); 1 g
chlorogenic acid; 500 mg trigonelline; and 1 g mannitol
as placebo. All supplements were dissolved in 270 mL
water.
The study consisted of four visits separated by at least
six days. During each visit participants ingested one of
the supplements 30 minutes before a 75 g oral glucose
tolerance test (OGTT). Seven venous blood samples
were taken via a cannula in the antecubital vein on each
visit following an overnight fast. The first two blood
samples were taken 30 minutes and immediately before
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the start of the OGTT. The other 5 blood samples were
taken 15, 30, 60, 90, and 120 minutes thereafter. For
measurement of intact GLP-1 the DPP-4 inhibitor
diprotin A (0.1 mmol/l, final concentration) was added
immediately after collection.
Plasma concentrations of total GLP-1, intact GLP-1
and total GIP were determined as previously described
[12,13]. Intra- and inter assay coefficients of variation
were 2% and 5%, respectively for intact GLP-1 and <6%
and <15%, respectively for both total GLP-1 and GIP.
Results for glucose and insulin concentrations have pre-
viously been presented [11].
The area under the curve (AUC) values for GLP-1 and
GIP were calculated using the trapezoidal method. Main
treatment effects relative to placebo for AUC values and
mean GLP-1 and GIP concentrations for individual time
points were analyzed using linear mixed regression
models. Bonferroni correction was used to adjust for
multiple comparisons. All tests were two-sided and P
values <0.05 were considered statistically significant.
Analyses were conducted using SPSS 17.0.
None of the treatments affected the area under the
curve values for total GLP-1, intact GLP-1, or total GIP
during the OGTT (Table 1). Decaffeinated coffee slightly
but significantly increased total GLP-1 concentration
relative to placebo at 30 minutes after ingestion (before
the OGTT) (2.7 pmol/L, 95%CI: 0.2;5.3, p = 0.03).
Chlorogenic acid and trigonelline did not significantly
affect incretin concentrations relative to placebo at any
of the time points (Figure 1).
In this randomized cross-over trial in healthy over-
weight men, decaffeinated coffee, chlorogenic acid and
trigonelline did not significantly affect the overall
response of GLP-1 or GIP to an OGTT relative to pla-
cebo. This is in line with the finding that these supple-
ments did not affect glucose and insulin area under the
curves in this study [11]. Decaffeinated coffee slightly
increased the total GLP-1 concentrations at 30 min after
ingestion (before the OGTT) relative to placebo. This
small change, although statistically significant, did not
coincide with changes in glucose and insulin levels [11].
Therefore this is probably a chance finding.
The lack of an effect of decaffeinated coffee on GLP-1
in our study is not in line with results of Johnston et al.
[9] who found an increased response. They also found
that ingestion of caffeinated and decaffeinated coffee
lowered GIP concentrations. This may be explained by
the fact that Johnston et al. [9] gave 25 g glucose
together with coffee, whereas we gave 75 g glucose 30
min after ingestion of the supplement. Potential differ-
ences in the type of coffee used in both studies probably
do not explain the different results since the type of cof-
fee and the concentration of chlorogenic acid were simi-
lar in the two studies [9,11]. Greenberg et al. [10] did
not find an overall effect of decaffeinated coffee on GIP
concentrations, which is in line with our results. How-
ever, they did find that decaffeinated coffee lowered GIP
concentrations at 60 minutes following ingestion of the
coffee (before the OGTT) relative to placebo and caf-
feine. In that study supplements were ingested 60 min
before the OGTT. We do not have data on the GIP
concentrations 60 min following ingestion of the supple-
ments alone, because the OGTT was administered at
30 min after ingestion of the supplements.
In conclusion, acute ingestion of decaffeinated coffee
and its major components chlorogenic acid and trigo-
nelline did not affect GLP-1 and GIP responses during
the oral glucose tolerance test. These findings do not
support the hypothesis that the putative beneficial effect
of coffee on the development of type 2 diabetes can be
explained by improved GLP-1 and GIP responses to
meals. Nevertheless, it cannot be excluded that habitual
coffee consumption in contrast to acute administration
may have an effect on incretin secretion.
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Table 1 Area under the curve during an oral glucose
tolerance test (mean ± SE) following ingestion of
chlorogenic acid, decaffeinated coffee, trigonelline and
placebo in 15 healthy overweight men
TOTAL
GLP-1
INTACT GLP-1* GIP
(pmol/L × 120 min)
Placebo 1720 ± 180 83 ± 33 6984 ± 566**
Chlorogenic acid 1549 ± 178 140 ± 47 6656 ± 620
Decaffeinated coffee 1809 ± 152 66 ± 21 6725 ± 516
Trigonelline 1730 ± 160 94 ± 39 7512 ± 619
*Intact GLP-1 concentrations were very low and a substantial number was at
the limit of detection and were reported as zero.
**n = 14 (1 missing value at time point 15 min.).
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Figure 1 Mean (± SE) plasma concentrations of total GLP-1 (A), intact GLP-1 (B) and GIP (C) before and throughout an OGTT,
following ingestion of chlorogenic acid, decaffeinated coffee, trigonelline and placebo in 15 healthy overweight men. Figure (A): At t =
0 decaffeinated coffee increased total GLP-1 concentration relative to placebo (p = 0.03).
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